These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Response kinetics of different classes of antibodies to SARS-CoV2 infection in the Japanese population: The IgA and IgG titers increased earlier than the IgM titers. Kurano M; Morita Y; Nakano Y; Yokoyama R; Shimura T; Qian C; Xia F; He F; Zheng L; Ohmiya H; Kishi Y; Okada J; Yoshikawa N; Nakajima K; Nagura Y; Okazaki H; Jubishi D; Moriya K; Seto Y; Yasui F; Kohara M; Wakui M; Kawamura T; Kodama T; Yatomi Y Int Immunopharmacol; 2022 Feb; 103():108491. PubMed ID: 34954559 [TBL] [Abstract][Full Text] [Related]
11. Methodological approaches to optimize multiplex oral fluid SARS-CoV-2 IgG assay performance and correlation with serologic and neutralizing antibody responses. Pisanic N; Antar AAR; Kruczynski KL; Gregory Rivera M; Dhakal S; Spicer K; Randad PR; Pekosz A; Klein SL; Betenbaugh MJ; Detrick B; Clarke W; Thomas DL; Manabe YC; Heaney CD J Immunol Methods; 2023 Mar; 514():113440. PubMed ID: 36773929 [TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin. Volk A; Covini-Souris C; Kuehnel D; De Mey C; Römisch J; Schmidt T BioDrugs; 2022 Jan; 36(1):41-53. PubMed ID: 34843105 [TBL] [Abstract][Full Text] [Related]
13. Antibody tests for identification of current and past infection with SARS-CoV-2. Deeks JJ; Dinnes J; Takwoingi Y; Davenport C; Spijker R; Taylor-Phillips S; Adriano A; Beese S; Dretzke J; Ferrante di Ruffano L; Harris IM; Price MJ; Dittrich S; Emperador D; Hooft L; Leeflang MM; Van den Bruel A; Cochrane Database Syst Rev; 2020 Jun; 6(6):CD013652. PubMed ID: 32584464 [TBL] [Abstract][Full Text] [Related]
14. A Combination of N and S Antigens With IgA and IgG Measurement Strengthens the Accuracy of SARS-CoV-2 Serodiagnostics. Jalkanen P; Pasternack A; Maljanen S; Melén K; Kolehmainen P; Huttunen M; Lundberg R; Tripathi L; Khan H; Ritvos MA; Naves R; Haveri A; Österlund P; Kuivanen S; Jääskeläinen AJ; Kurkela S; Lappalainen M; Rantasärkkä K; Vuorinen T; Hytönen J; Waris M; Tauriainen S; Ritvos O; Kakkola L; Julkunen I J Infect Dis; 2021 Jul; 224(2):218-228. PubMed ID: 33905505 [TBL] [Abstract][Full Text] [Related]
15. Kinetics of specific anti-SARS-CoV-2 IgM, IgA, and IgG responses during the first 12 months after SARS-CoV-2 infection: A prospective longitudinal study. Amellal H; Assaid N; Charoute H; Akarid K; Maaroufi A; Ezzikouri S; Sarih M PLoS One; 2023; 18(7):e0288557. PubMed ID: 37437051 [TBL] [Abstract][Full Text] [Related]
16. Longitudinal analysis to characterize classes and subclasses of antibody responses to recombinant receptor-binding protein (RBD) of SARS-CoV-2 in COVID-19 patients in Thailand. Tandhavanant S; Koosakunirand S; Kaewarpai T; Piyaphanee W; Leaungwutiwong P; Luvira V; Chantratita N PLoS One; 2021; 16(8):e0255796. PubMed ID: 34375345 [TBL] [Abstract][Full Text] [Related]
17. COVID-19 Serology at Population Scale: SARS-CoV-2-Specific Antibody Responses in Saliva. Pisanic N; Randad PR; Kruczynski K; Manabe YC; Thomas DL; Pekosz A; Klein SL; Betenbaugh MJ; Clarke WA; Laeyendecker O; Caturegli PP; Larman HB; Detrick B; Fairley JK; Sherman AC; Rouphael N; Edupuganti S; Granger DA; Granger SW; Collins MH; Heaney CD J Clin Microbiol; 2020 Dec; 59(1):. PubMed ID: 33067270 [TBL] [Abstract][Full Text] [Related]
18. Optimisation and Validation of a conventional ELISA and cut-offs for detecting and quantifying anti-SARS-CoV-2 Spike, RBD, and Nucleoprotein IgG, IgM, and IgA antibodies in Uganda. Oluka GK; Namubiru P; Kato L; Ankunda V; Gombe B; Cotten M; ; Musenero M; Kaleebu P; Fox J; Serwanga J Front Immunol; 2023; 14():1113194. PubMed ID: 36999017 [TBL] [Abstract][Full Text] [Related]